Innate Pharma S.A.

As of June 30, 2026, cash equivalents and financial assets were €21.4 million. That balance excluded the $75 million Sobi upfront payment, equivalent to about €65 million, and the €30 million equity offering (about €28 million expected net proceeds). Management said the combination of the Sobi upfront and equity proceeds is expected to extend cash runway through the end of Q1 2028. The call did not report revenue, EPS, or gross margin figures. Forward looking items included TELLOMAK-3 first patient expected in Q1 2027, an accelerated approval filing for lacutamab planned for 2H 2027, IPH4.5 thousand initial Phase 1 data on November 18, 2026, and PACIFIC-9 Phase 3 readout expected in 2H 2026.

Jonathan E. Dickinson framed the period as one of ‘important progress across our focus portfolio,’ driven by the Sobi partnership, advancing IPH4.5 thousand, and completed monalizumab enrollment. His tone was constructive and catalyst-focused, repeatedly pointing to multiple near-term milestones. He also underscored that the Sobi deal and financing strengthen the balance sheet and support execution into 2028.

Frederic Lombard said cash equivalents and financial assets were €21.4 million at June 30, 2026, excluding the $75 million Sobi upfront and the equity proceeds. He said the equity raise was €30 million gross and about €28 million expected net, and that the primary uses are continued clinical development of IPH4.5 thousand, advancement of the preclinical ADC portfolio, and general corporate purposes. He reiterated that, together with the Sobi upfront payment, these proceeds are expected to extend runway through the end of Q1 2028.

Analysts focused on IPH4.5 thousand safety versus prior ADCs, with management saying the linker was designed for stability and that preclinical and primate data suggest limited free-payload release, which they believe may reduce systemic hematologic toxicity. They also said the upcoming dataset from 76 patients across 11 indications should provide meaningful safety and response data to guide next steps. On lacutamab, management said they expect NCCN listing after accelerated approval, see potential first-line off-label use, and said US payer work supports pricing between $500 thousand and $650 thousand per patient per annum. For PACIFIC-9, they said AstraZeneca is expected to issue a press release and Innate also plans to do so, with potential follow-up calls.